A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamos Non-Small Cell Lung Cancer That is Stage IIIB, Stage IV or Recurrent
Sponsor: |
Incyte Corporation |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAN7916 |
U.S. Govt. ID: |
NCT02119650 |
Contact: |
Balazs Halmos: 212-305-5874 / bh2376@columbia.edu |
The purpose of this study is to find out whether the drug, ruxolitinib, is effective, tolerable and safe in combination with two chemotherapy medicines called pemetrexed and cisplatin. The study will test if this combination has beneficial effects in people diagnosed with certain types of non-small cell lung cancer. Only participants with Stage IIIB, Stage IV or recurrent non-small cell lung cancer may participate.
This study is closed
Investigator
Balazs Halmos, MD
Do you have Stage IIIB, Stage IV or recurrent non small cell lung cancer? |
Yes |
No |
Do currently suffer from any uncontrolled (untreated) cardiac disease? |
Yes |
No |